Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
The molecule is an azo derivative of an active molecule (UR-12715, PAF antagonist and anti-TNFa) and 5-aminosalicylic acid (5-ASA), the gold standard treatment for mild to moderate ulcerative colitis More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
A fractionated herbal extract (STD052) demonstrating cholesterol/triglyceride lowering properties, purified down to a single active compound (STD07), a potential drug candidate for the treatment of GI disorders. More
Anti-peptic ulcer, anti-gastritis More
The University of Edinburgh has developed a new method of screening for polymorphs and solvates of drug compounds that has potential to revolutionise the way polymorph screening is conducted. More
Diurea lead compounds that block intracellular signal transduction More
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models. More
Scientists at the University of Edinburgh have identified a novel therapeutic strategy for the treatment of inflammatory disorders. More
Your selection
Browse By
- Industry sector
- Bioinformatics
- Bioinformatics
- Combinatorial biology
- Combinatorial chemistry
- Drug research platforms
- Genomics
- High throughput screening
- Proteomics
- Therapeutic target
- Appendicitis
- Cholangitis, sclerosing
- Colitis
- Colitis, ulcerative
- Constipation
- Crohn's disease
- Diarrhea
- Dyspepsia
- Electrolyte replacement
- Emesis
- Emesis, motion
- Esophagitis
- Flatulence
- Food poisoning
- Gastritis
- Gastroesophageal reflux disorder
- Gastrointestinal (other)
- Gastrointestinal secretions
- Gastroprokinetic
- Helicobacter pylori
- Inflammatory bowel disease
- Irritable bowel syndrome
- Nausea
- Pancreatitis
- Ulcer
- Ulcer, gastric
- Ulcer, gastroduodenal
- Ulcer, peptic
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us